Skip to main content

Table 5 PCR-corrected adequate clinical and parasitological response (ACPR) of artesunate-amodiaquine

From: The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data

  Survival estimates on day 28 a, b Survival estimates on day 42 a, b
  FDC Co-blistered NFDC c Loose NFDC-30 Loose NFDC-25 c FDC Loose NFDC-30
Age category At risk K-M [95% CI] At risk K-M [95% CI] At risk K-M [95% CI] At risk K-M [95% CI] At risk K-M [95% CI] At risk K-M [95% CI]
<1 y 207 97.8 [95.9-99.7] 77 98.7 [96.3-100] 222 93.8 [90.7-96.8] 95 90.9 [85.6-96.1] 42 95.6 [90.9-100] 28 85.7 [76.6-94.9]
1 to <5 y 2,044 97.9 [97.3-98.5] 511 96.9 [95.4-98.3] 1,340 94 [92.8-95.2] 532 92.2 [90.2-94.2] 325 95.7 [94-97.3] 103 92.5 [90-94.9]
5 to <12 y 565 98.1 [97-99.2] 192 98.6 [97-100] 317 98.8 [97.5-100] 211 97.4 [95.3-99.5] 65 95.4 [91.6-99.2] 15 98.8 [97.5-100]
≥12 y 570 98.6 [97.6-99.5] 203 99.6 [98.9-100] 140 98.6 [96.7-100] 31 100 [88.9-100.0]d 142 97.9 [96.3-99.5] 34 93.2 [86.2-100]
Region             
West Africa 2,167 98.1 [97.6-98.7] 959 97.8 [96.9-98.7] 337 94.9 [92.6-97.2] - - 257 95.3 [93.3-97.3] - -
East Africa 299 98.9 [97.8-100] 24 100 [100-100] 921 92.8 [91.2-94.4] 869 93.4 [91.9-94.9] 81 98.9 [97.8-100] 127 89.5 [86.3-92.7]
Rest of Africa 615 98.6 [97.8-99.5] - - 664 98.3 [97.3-99.2] - - 124 97.1 [94.8-99.4] - -
Asia 305 95.5 [93.2-97.7] - - 69 93.2 [87.5-99] - - 112 93.8 [90.7-97] 53 90.2 [83.3-97.1]
S America - - - - 30 100 [88.7-100]d - - - - - -
Overall 3,386 98.1 [97.6-98.5] 983 97.9 [97-98.8] 2,021 95 [94.1-95.9] 869 93.4 [91.9-94.9] 574 96.1 [95-97.3] 180 92.1 [89.8-94.4]
  1. aKaplan-Meier estimates were generated using all the individual data rather than combining estimates from individual trials. n is the number of patients at risk (n) on day 28.
  2. bPairwise comparisons at day 28 using the Mantel-Haenszel (log-rank ) test.
  3. FDC v co-blistered NFDC (P = 0.799).
  4. FDC v loose NFDC-30 (P < 0.001).
  5. FDC v loose NFDC-25 (P < 0.001).
  6. Co-blistered NFDC v loose NFDC-30 (P < 0.001).
  7. Co-blistered NFDC v loose NFDC-25 (P < 0.001).
  8. Loose NFDC-30 v loose NFDC-25 (P = 0.036).
  9. cPatients followed up only up to 28 days.
  10. dExact confidence intervals using Wilson’s method using number of patients at risk on the given day.